Datapoint: Express Scripts Adds Humira Biosimilars to Its Formulary

Cigna Corp.’s Express Scripts last week said it will add biosimilars to AbbVie’s Humira to its 2023 formularies as preferred products, joining Optum Rx, which announced a similar move last month. “This decision helps us achieve lower costs for patients and plans while giving patients and providers choice and flexibility as additional biosimilars come to market,’ Harold Carter, chief pharma trade relations officer at Express Scripts, said in a statement. Express Scripts currently covers Humira as a preferred drug for 14.1% of all insured lives, growing to 95.5% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 12/7/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 30

Datapoint: BMS to Battle AstraZeneca in Court Over Yervoy-Imjudo Dispute

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 26

Datapoint: Elevance Health to Acquire BCBS Louisiana

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 25

Datapoint: Seagen Scores Colorectal Cancer Nod for Tukysa

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today